# Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation

> **NCT02790515** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **St. Jude Children's Research Hospital** · enrollment: 170 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia (ALL)
- Acute Myeloid Leukemia (AML)
- Myeloid Sarcoma
- Chronic Myeloid Leukemia (CML)
- Juvenile Myelomonocytic Leukemia (JMML)
- Myelodysplastic Syndrome (MDS)
- Non-Hodgkin Lymphoma (NHL)

## Interventions

- **DRUG:** Anti-thymocyte globulin (rabbit)
- **DRUG:** Blinatumomab
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** G-CSF
- **DRUG:** Melphalan
- **DRUG:** Mesna
- **DRUG:** Rituximab
- **DRUG:** Tacrolimus
- **DRUG:** Thiotepa
- **BIOLOGICAL:** HPC,A Infusion
- **DEVICE:** CliniMACS
- **DRUG:** Sirolimus

## Key facts

- **NCT ID:** NCT02790515
- **Lead sponsor:** St. Jude Children's Research Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-07-14
- **Primary completion:** 2025-07-01
- **Final completion:** 2026-07-01
- **Target enrollment:** 170 (ACTUAL)
- **Last updated:** 2025-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02790515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02790515, "Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02790515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*